Thomas, N., & Ting, N
Emerging evidence has shown that GL also possesses significant antioxidant activity both in vivo and in vitro
In a 40-week Phase 3 trial, adults with type 2 diabetes taking 12 mg of retatrutide shed an average of 16.8% (36.6 lbs) of their beginning weight
Your doctor should conduct regular monitoring during Zepbound treatment, including weight and vital signs at each visit, periodic assessment of obesity-related conditions, monitoring for adverse effects (including potential pancreatitis, gallbladder disease, dehydration, or allergic reactions), and laboratory testing as indicated (such as hemoglobin A1c if you have diabetes)
Discontinuing prescribed therapy may lead to a rebound in body weight
[12] [1] If pancreatitis is suspected (persistent, severe abdominal pain), Rybelsus should be discontinued immediately and urgent medical assessment sought